Impact ledger
Gilead Sciences, Inc. (GILD): the developments shaping its investment case
Follow the evidence affecting Gilead Sciences, Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-09-02 | revenue | Bullish | FDA approval of Bixlenvo led to an upgrade in 2026 HIV franchise revenue growth guidance to 9-10%. |
| 2026-09-02 | revenue | Bullish | FDA approval for Bixlenvo led to an upgrade in 2026 HIV franchise revenue growth projection to 9-10%. |
Event impact log
9 events mapped to GILD since 2026-08-27. Evidence through 2026-09-16.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-16 | CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth | Direct revenue growth from increased adoption and market expansion of existing CAR-T therapies (Yescarta, Tecartus) in hematologic oncology. | Bullish | 1-5y | 0.70 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff | Indirectly through competitive landscape and investor sentiment towards companies with strong HIV/antiviral franchises and R&D pipelines. | watch | 3-12m | 0.30 |
| 2026-09-11 | GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff | Indirect competitive pressure and market dynamics in the HIV and oncology spaces. GSK's pipeline activity could signal future competitive shifts. | watch | 1-3m | 0.30 |
| 2026-09-08 | Eli Lilly Accelerates Biotech Acquisitions to Dilute GLP-1 Revenue Concentration | Increased competitive pressure for biotech acquisition targets, potential for higher acquisition premiums, or strategic response to LLY's diversification. | watch | 3-12m | 0.40 |
| 2026-09-06 | Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand | Potential for increased sales of Jyseleca (filgotinib), a JAK inhibitor, in regions where it is approved for atopic dermatitis, benefiting from overall market growth. | Bullish | 1-5y | 0.40 |
| 2026-09-02 | Gilead secures FDA approval for Bixlenvo and lifts 2026 HIV sales outlook | Direct impact from new drug approval and increased sales guidance. | Bullish | 3-12m | 0.80 |
| 2026-09-02 | Gilead secures FDA approval for Bixlenvo, raises 2026 HIV sales outlook to 9-10% | Direct product approval and increased sales guidance, mitigating patent cliff concerns. | Bullish | 1-3m | 0.80 |
| 2026-09-02 | FDA approves Gilead's Bixlenvo as HIV franchise sales outlook raised to 9-10% | Direct product approval and increased sales guidance for a core franchise. | Bullish | 1-3m | 0.80 |
| 2026-08-27 | Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch | Potential future competition or partnership in regenerative medicine/cell therapy space | watch | 3-12m | 0.20 |
Continue this research
Build your Gilead Sciences, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the GILD entity page →